Oral Taxane Solid Dispersion for High Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral taxane formulations face challenges with low bioavailability and low active ingredient loading due to poor solubility and efflux by multidrug transporters, leading to inefficient clinical dosing regimens.
Innovation Solution
A high-strength, high-bioavailability oral composition of taxanes is achieved through a solid dispersion of docetaxel with hypromellose acetate succinate (HPMCAS) carrier, compressed into tablets, which maintains supersaturated solubility and release in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If solid dispersion formulation is used to improve solubility and bioavailability of taxanes, then bioavailability is improved, but the bulk density remains low and active ingredient loading per capsule is limited
Solution Approach 1:
The patent changes the physical state of the taxane from crystalline to amorphous, which fundamentally alters its solubility parameters. The amorphous form achieves supersaturated solubility in the gastrointestinal tract, maintaining high bioavailability while enabling higher active ingredient loading in the final dosage form.
Solution Approach 2:
The patent creates a composite material system consisting of amorphous taxane dispersed in a solid matrix containing solubility-enhancing excipients. This composite structure maintains the supersaturated state of the amorphous taxane while providing mechanical stability for high-loading dosage forms.
2Reliability
If conventional solid dispersion is filled into capsules, then bioavailability is improved, but the light and fluffy nature limits the volume of powder and active loading per capsule
Solution Approach 1:
The patent transforms the physical parameters of the solid dispersion by compressing it into a tablet form. This changes the bulk density and mechanical properties from light and fluffy to compact and dense, enabling high active ingredient loading within practical dosage form dimensions.
Solution Approach 2:
The patent transitions from a powder-filled capsule (one-dimensional packing) to a compressed tablet (three-dimensional compact structure). This dimensional change allows much higher active ingredient loading by utilizing the full volumetric capacity of the dosage form.
3Reliability
If poor solvents and liquid bridging solvents are used to form emulsion and solid microspheres, then solubility is enhanced, but the microspheres have hollow centers and are not suitable for compression into high dosage forms
Solution Approach 1:
The patent changes the solvent system from organic poor solvents and liquid bridging solvents to aqueous-based systems. This parameter change enables the formation of solid dispersions with dense, non-hollow structures that are suitable for compression into high-dosage tablets.
Solution Approach 2:
The patent utilizes phase transition of water from liquid to solid state during drying, forming a solid matrix that traps the amorphous taxane in a supersaturated state. This creates a dense, compressible structure unlike the hollow microspheres formed by organic solvent systems.
4Reliability
If substantial amount of dispersant such as porous silica is included to increase bioavailability, then bioavailability is improved, but the ability to achieve high active loading content is limited
Solution Approach 1:
The patent changes the functional role of excipients from using substantial amounts of porous silica dispersants to using smaller amounts of solubility-enhancing excipients that work synergistically with the amorphous taxane. This parameter change in excipient type and amount enables high active loading while maintaining bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides sustained supersaturated solubility of taxanes for at least 3 hours, allowing for high active ingredient loading up to 14% in tablets, enhancing patient compliance and bioavailability.
Implementation Method 1
maintains supersaturated solubility and release in the gastrointestinal tract
Implementation Method 2
comprised of a solid dispersion of docetaxel and a hypromellose acetate succinate (HPMCAS) carrier
Data Source
Figure 1~2A
Figure 2B~3A
Figure 3B~4A
AI summary
The inventive subject matter provides compositions and methods for producing high dose, high bioavailability oral taxane compositions. Oral taxanes are prepared as an amorphous solid dispersion, and can be provided in a compressed tablet form. Surprisingly oral bioavailability of taxanes prepared and provided in this matter is high, even in the absence of surfactants.